A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01196143
First received: April 19, 2010
Last updated: February 3, 2014
Last verified: February 2014

April 19, 2010
February 3, 2014
October 2008
January 2011   (final data collection date for primary outcome measure)
Live birth rate [ Time Frame: Up to 28 days after birth ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01196143 on ClinicalTrials.gov Archive Site
  • Pregnancy rate (ongoing, clinical, biochemical) [ Time Frame: up to 40 weeks post embryo-transfer ] [ Designated as safety issue: No ]
    Biochemical: up to 2 weeks post embryo-transfer / clinical: up to 12 weeks post embryo-transfer / ongoing: up to 40 weeks post embryo-transfer
  • Fertilization rate [ Time Frame: 24 hours post oocyte retrieval ] [ Designated as safety issue: No ]
  • Implantation rate [ Time Frame: 2 weeks post embryo-transfer ] [ Designated as safety issue: No ]
  • Detailed record of adverse events [ Time Frame: Up to 1 year after subject enrollment ] [ Designated as safety issue: Yes ]
  • Hormone (E2) levels on hCG day [ Time Frame: Up to 12 hours prior to hCG administration ] [ Designated as safety issue: No ]
  • Duration of treatment [ Time Frame: Up to 12 hours post last FSH injection ] [ Designated as safety issue: No ]
  • Total amount of FSH administered [ Time Frame: Up to 1 hour post last FSH injection ] [ Designated as safety issue: No ]
  • Number of oocytes [ Time Frame: Up to 1 hour post oocyte retrieval ] [ Designated as safety issue: No ]
  • Miscarriage rate [ Time Frame: Up to 12 weeks post embryo-transfer ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation
Non-interventional Observational Study to Evaluate the Baseline FSH, Ovarian Volume and AFC (Antral Follicle Count) as Prognostic Factors of the Outcome of the In-vitro Fertilization/Intracytosolic Sperm Injection (IVF/ICSI) in Infertile Patients Who Receive r-FSH (GONAL-f®) for Controlled Ovarian Hyperstimulation

This is a phase IV non-interventional, multicentric observational study to evaluate the baseline follicle stimulating hormone (FSH) levels, ovarian volume, antral follicle count (AFC) and age as prognostic factors of the outcome of the in-vitro fertilisation/intracytosolic sperm injection (IVF/ICSI) in infertile subjects receiving Gonal-f for controlled ovarian hyperstimulation (COH).

Treatment of subfertility and infertility by assisted reproduction technologies (ART) such as IVF and embryo transfer (ET) requires multiple follicular development to increase the number of female gametes, and the chances of a successful treatment outcome. These technologies include the stimulation of multiple follicular development by exogenous FSH administration and the suppression of endogenous luteinizing hormone (LH) secretion by administration of a GnRH analogue (antagonist or agonist, as required). A single dose of human chorionic gonadotropin (hCG) is administered to mimic the endogenous LH surge and induce final oocyte maturation after adequate follicular development. Recombinant-hFSH (r-hFSH) has been shown to be efficacious in terms of number of oocytes recovered and in terms of pregnancy rates as compared to urinary-hFSH.

Gonal-f fill-by-mass is available as a liquid formulation that can be administered with the pen device. The pen device is prefilled and hence the subject does not require to assemble the device making it simpler to use. The prefilled pen allows the accurate delivery of a precise dose of r-hFSH in 37.5 International Units (IU) increments.

OBJECTIVES

Primary objective:

  • Evaluation of the significance of baseline FSH, ovarian volume and AFC with a model adjusted for age as prognostic factors of the IVF/ICSI treatment outcome.

This study planned to enrol 500 female subjects undergoing COH for IVF/ICSI-treatment with Gonal-f. Gonal-f will be administered daily subcutaneously (s.c.) according to the centre's usual clinical practice, commencing on Days 2 or 3 of the cycle during the stimulation period. Treatment with Gonal-f will be continued until adequate follicular development has been achieved with the dose adjusted according to the subject's response, to usually not higher than 450 IU daily. A single injection of 250 micrograms r-hCG or 5,000 IU up to 10,000 IU hCG would be administered 24-48 hours after the last Gonal-f injection to induce final follicular maturation. Gonal-f will be started approximately 2 weeks after the start of an gonadotrophin-releasing hormone (GnRH) agonist treatment, both being continued until adequate follicular development will be achieved. Oocyte retrieval will be done 34-36 hours after hCG administration followed by IVF/ICSI treatment according to clinic's protocol. Each enrolled subject would be followed up until the confirmation of her pregnancy status. Active follow up of all pregnancies will be performed, including those subjects withdrawn from the study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Plasma, serum, urine

Non-Probability Sample

Subjects undergoing COH for IVF/ICSI-treatment with Gonal-f in Greece.

Infertility
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
356
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pre-menopausal female subjects aged between 20-43 years
  • Subjects requiring treatment with recombinant FSH for COH for IVF and/or ICSI
  • Subjects who are able to communicate well with the investigator and can comply with the requirements of the entire study
  • Subjects who have given written informed consent, prior to treatment, with the understanding that consent may be withdrawn by the subject at any time without prejudice

Exclusion Criteria:

  • Female subjects not pregnant or lactating
  • Subjects with known allergic reaction against one of the ingredients
  • Subjects with enlarged ovaries or cysts unrelated to polycystic ovarian disease.
  • Subjects with gynaecological bleeding of unknown origin
  • Subjects with ovarian, uterine, or mammary cancer
  • Subjects with hyperprolactinaemia
  • Subjects with tumors of the hypothalamus or the pituitary gland
Female
20 Years to 43 Years
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
NCT01196143
700623-503
Not Provided
Merck KGaA
Merck KGaA
Not Provided
Study Director: Michalis Arvanitis, MD, MSc Merck A.E. Hellas,Greece, an affiliate of MerckKGaA, Darmstadt, Germany
Merck KGaA
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP